SARS Vaccine Development
subject: Keywords: SARS, SARS-CoV, spike protein, receptor-binding domain, Neutralizing epitone, vaccine
description: Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.
creator: Shibo Jiang, Yuxian He, Shuwen Liu
source: Emerging Infectious Diseases
publisher: Centers for Disease Control and Prevention
date: 2005
language: EN
identifier: DOI: 10.3201/eid1107.050219
coverage: Infectious and parasitic diseases, Medicine